DBVT News

Biotech companies lead a weak week in IPOs. So far this year, 127 companies have come public, and the average first-day pop has been about 16%. In the past two weeks, 8 of 12 IPOs ended their first day down or flat. The downward trend accelerated this week with an average first-day return...read more

Aimmune Therapeutics, which is developing an oral immunotherapy to desensitize peanut allergies, raised $160 million by offering 10 million shares at $16.00, the high end of the range of $14 to $16. Aimmune Therapeutics plans to list on the Nasdaq under the symbol AIMT. BofA Merrill Lynch, Credit Suisse and Piper Jaffray acted as lead managers on the deal. ...read more

Aimmune Therapeutics, which is developing an oral immunotherapy designed to lessen the effects of peanut allergies, announced terms for its IPO on Monday. The Brisbane, CA-based company plans to raise $125 million by offering 8.3 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Aimmune Therapeutics would command a fully diluted market value...read more

Aimmune Therapeutics, which is developing an oral immunotherapy designed to lessen the effects of peanut allergies, filed on Monday with the SEC to raise up to $115 million in an initial public offering. The company notes that it may face competition DBV Technologies (DBVT), which is developing an immunotherapy patch for food allergies, including peanut. The French biotech...read more